問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Nuclear Medicine

Division of Hematology & Oncology

Taoyuan Chang Gung Memorial Hospital of The C.G.M.F. (在職)

Division of Nuclear Medicine

更新時間：2023-09-19

閻紫宸Yen, Tzu-Chen
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 11 個月

  • yentc1110@gmail.com

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

閻紫宸

List

65Cases

2017-07-01 - 2022-07-30

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

  • Condition/Disease

    Mild Alzheimer's Disease

  • Test Drug

    Crenezumab

Participate Sites
7Sites

Terminated6Sites

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

2008-04-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-03-01 - 2019-12-31

Phase II

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    UBITh AD Immunotherapeutic Vaccine (UB-311)

Participate Sites
4Sites

Terminated4Sites

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2009-08-01 - 2010-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-07-01 - 2012-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2009-08-01 - 2010-07-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2009-01-01 - 2009-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2008-08-01 - 2011-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-01-01 - 2010-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB